Characterizing SOD1 mutations in Spain. The impact of genotype, age, and sex in the natural history of the disease.

Amyotrophic lateral sclerosis SOD1 motor neuron disease mutation prevalence prognosis

Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
09 Dec 2022
Historique:
revised: 16 10 2022
received: 13 07 2022
accepted: 04 11 2022
entrez: 9 12 2022
pubmed: 10 12 2022
medline: 10 12 2022
Statut: aheadofprint

Résumé

The aim of this study is to describe the frequency and distribution of SOD1 mutations in Spain, and to explore those factors contributing to their phenotype and prognosis. Seventeen centres shared data on amyotrophic lateral sclerosis (ALS) patients carrying pathogenic or likely pathogenic SOD1 variants. Multivariable models were used to explore prognostic modifiers. In 144 patients (from 88 families), 29 mutations (26 missense, 2 deletion/insertion and 1 frameshift) were found in all 5 exons of SOD1, including 7 novel mutations. 2.6% of ALS patients (including 17.7% familial and 1.3% sporadic) were estimated to carry SOD1 mutations. Its frequency varied considerably between regions, due to founder events. The most frequent mutation was p.Gly38Arg (n = 58), followed by p.Glu22Gly (n = 11), p.Asn140His (n = 10), and the novel p.Leu120Val (n = 10). Most mutations were characterized by a protracted course, and some of them by atypical phenotypes. Older age of onset was independently associated with faster disease progression (exp(Estimate) = 1.03 [0.01, 0.05], p = 0.001) and poorer survival (HR = 1.05 [1.01, 1.08], p = 0.007), regardless of the underlying mutation. Female sex was independently associated to faster disease progression (exp(Estimate) = 2.1 [1.23, 3.65], p = 0.012) in patients carrying the p.Gly38Arg mutation, resulting in shorter survival compared with male carriers (236 vs 301 months). These data may help to evaluate the efficacy of SOD1 targeted treatments, and to expand the number of patients that might benefit from these treatments.

Identifiants

pubmed: 36484631
doi: 10.1111/ene.15661
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

This article is protected by copyright. All rights reserved.

Auteurs

Juan F Vázquez-Costa (JF)

Neuromuscular Unit, Hospital Universitario y Politécnico la Fe, IIS La Fe, Valencia, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain.
Department of Medicine, Universitat de València, Valencia, Spain.

Daniel Borrego-Hernández (D)

Neurology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain.

Carmen Paradas (C)

Hospital Universitario Virgen del Rocío and Instituto Biomedicina de Sevilla, Sevilla, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain.

María Teresa Gómez-Caravaca (MT)

Hospital Universitario Reina Sofía, Córdoba, Spain.

Ricardo Rojas-Garcia (R)

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain.
Motor Neuron Diseases Clinic, Department of Neurology, Biomedical Research Institute Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Luis Varona (L)

Department of Neurology, Hospital Universitario de Basurto, Bilbao, Spain.

Mónica Povedano (M)

Department of Neurology, Hospital de Bellvitge and Idibell, Barcelona, Spain.

Tania García-Sobrino (T)

Department of Neurology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela (A Coruña), Spain.

Ivonne Jericó Pascual (I)

Hospital Universitario de Navarra (HUN) and IdisNA, Pamplona, Spain.

Antonio Gutiérrez (A)

Complejo Hospitalario Universitario Insular-Materno-Infantil de Gran Canaria, Gran Canaria, Spain.

Javier Riancho (J)

Hospital Sierrallana-IDIVAL. Departamento de Medicina y Psiquiatría. Universidad Cantabria. Cantabria, Spain.

Janina Turon-Sans (J)

Motor Neuron Diseases Clinic, Department of Neurology, Biomedical Research Institute Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Abdelilah Assialioui (A)

Department of Neurology, Hospital de Bellvitge and Idibell, Barcelona, Spain.

Jordi Pérez-Tur (J)

Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain.
Institut de Biomedicina de València-CSIC. CIBERNED. Unidad Mixta de Neurología y Genética. IIS La Fe. Valencia, Spain.

Teresa Sevilla (T)

Neuromuscular Unit, Hospital Universitario y Politécnico la Fe, IIS La Fe, Valencia, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain.
Department of Medicine, Universitat de València, Valencia, Spain.

Jesús Esteban Pérez (J)

Neurology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain.

Alberto García-Redondo (A)

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain.
Neurology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain.

Classifications MeSH